<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02403505</url>
  </required_header>
  <id_info>
    <org_study_id>ANDA208414</org_study_id>
    <secondary_id>FWA00015357</secondary_id>
    <secondary_id>IORG0007849</secondary_id>
    <secondary_id>IRB00009424</secondary_id>
    <secondary_id>ANDA208414</secondary_id>
    <secondary_id>IND78420</secondary_id>
    <secondary_id>NPI1831468511</secondary_id>
    <secondary_id>NPI1023387701</secondary_id>
    <nct_id>NCT02403505</nct_id>
  </id_info>
  <brief_title>Discovery Stage Clinical Study About Oncology Drugs and Single Nucleotide Polymorphisms</brief_title>
  <acronym>Drugs-SNPs</acronym>
  <official_title>Discover the Relationship Between the Oncology Drug Therapeutic Efficacy and the Relative Drug Target SNP Genotyping, and the Relationship Between the Oncology Drug Therapeutic Safety and the Relative Drug Target SNP Genotyping.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Medicine Invention Design, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      That current oncology drugs on USA market have the universal problems about low effectiveness
      of pharmacology to cancer cells and high risk of toxicology to normal cells can demonstrate
      following most significantly and most reasonably: it is not enough so far away that just only
      oncology drug target molecules as cancer patient-specific biomarkers directly; it must be
      that oncology drug targets' SNPs like as real personalized or individualized cancer
      patient-specific biomarkers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Sponsor-Investigator's discovery human subjects' study, the investigators will use the
      ABIRATERONE plus PREDNISONE plus ENZALUTAMIDE (300 patients - Group 1) or the ABIRATERONE
      plus PREDNISONE plus NILANDRON (300 patients - Group 2) to treat Prostate Cancer patients and
      will try to look for the relationship between the ABIRATERONE ACETATE TABLET therapeutic
      efficacy and the drug target CYP17 SNP Genotyping, and the relationship between the
      ABIRATERONE ACETATE TABLET therapeutic safety and the drug target CYP1A2, CYP2C8, CYP2C9,
      CYP2C19, CYP2D6, CYP3A4/5, CYP17 and SULT2A1 SNP Genotyping.

      According to ABIRATERONE ACETATE TABLET Labeling Directions, the ABIRATERONE drug target
      CYP17 should be effectiveness-associated; and the ABIRATERONE drug target CYP1A2, CYP2C8,
      CYP2C9, CYP2C19, CYP2D6, CYP3A4/5, CYP17 and SULT2A1 should also be risk-associated. The
      investigators hope to discover the CYP17 SNP Genotypes which may be effectiveness-associated,
      and the CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4/5, CYP17 and SULT2A1 SNP Genotypes
      which may be risk-associated.

        -  1) Detect drug target whole gene precision sequence of everyone patient for all 600
           recruited double blind prostate cancer patients.

        -  2) Mutually compare everyone patient drug target whole gene precision sequence for total
           600 recruited double blind prostate cancer patients.

        -  3) Calculate drug target gene SNPs in all 600 recruited double blind prostate cancer
           patients.

        -  4) Correlate everyone patient drug target gene SNP to everyone patient drug efficacy.

        -  5) Correlate everyone patient drug target gene SNP to everyone patient drug safety.

        -  6) Mutually compare the usual approach group SNPs (Group -1 -- 300 double blind random
           group separated prostate cancer patients) with the study approach group SNPs (Group - 2
           -- 300 double blind random group separated prostate cancer patients).

        -  7) Confirm the relationship between drug target gene SNPs and drug efficacy.

        -  8) Confirm the relationship between drug target gene SNPs and drug safety.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2, 2017</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants with Effective Events as a Measure of Efficacy</measure>
    <time_frame>1 Time per 180 Days</time_frame>
    <description>Nothing metastatic and recurrent like as Effective Events in combined chemotherapies after local therapy with surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants with Adverse Events as a Measure of Safety</measure>
    <time_frame>1 Time per 180 Days</time_frame>
    <description>Leukopenia like as Adverse Events in combined chemotherapies after local therapy with surgery</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The Number of Participants with ABIRATERONE drug target gene SNPs associated to Effective Events in prostate cancer cells as a Measure of Efficacy</measure>
    <time_frame>1 Time per 180 Days</time_frame>
    <description>The Prostate tissue or lymph node cancer cell whole genome DNA isolations</description>
  </other_outcome>
  <other_outcome>
    <measure>The Number of Participants with ABIRATERONE drug target gene SNPs associated to Adverse Events in Peripheral blood WBCs as a Measure of Safety</measure>
    <time_frame>1 Time per 180 Days</time_frame>
    <description>The Peripheral blood WBC whole genome DNA isolations</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Stage, Prostate Cancer</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>ABIRATERONE - Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZYTIGA - ABIRATERONE ACETATE TABLET
Combined Chemotherapy
DELTASONE- PREDNISONE TABLET
XTANDI - ENZALUTAMIDE CAPSULE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABIRATERONE - Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ZYTIGA - ABIRATERONE ACETATE TABLET
Combined Chemotherapy
DELTASONE- PREDNISONE TABLET
NILANDRON - NILUTAMIDE TABLET</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABIRATERONE - Group 1</intervention_name>
    <description>ZYTIGA - ABIRATERONE ACETATE TABLET plus DELTASONE - PREDNISONE TABLET plus XTANDI - ENZALUTAMIDE CAPSULE</description>
    <arm_group_label>ABIRATERONE - Group 1</arm_group_label>
    <other_name>ABIRATERONE plus PREDNISONE plus ENZALUTAMIDE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABIRATERONE - Group 2</intervention_name>
    <description>ZYTIGA - ABIRATERONE ACETATE TABLET plus DELTASONE - PREDNISONE TABLET plus XTANDI - NILANDRON - NILUTAMIDE TABLET</description>
    <arm_group_label>ABIRATERONE - Group 2</arm_group_label>
    <other_name>ABIRATERONE plus PREDNISONE plus NILUTAMIDE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of prostate cancer

          -  Clinical biopsy diagnosis of prostate cancer

          -  Suitable for local therapy with surgery

          -  Random and double blind

          -  Measurable disease

          -  Adequate organ functions

          -  Adequate performance status

          -  Age 22 years old and over

          -  Sign an informed consent form

        Exclusion Criteria:

          -  Treatment with other anti-cancer therapies and cannot be stopped currently

          -  Pregnancy

          -  Breast-feeding

          -  The patients with other serious inter-current illness or infectious diseases

          -  Have more than one different kind of cancer in the same time

          -  Allergy to drugs

          -  Serious Bleed Tendency

          -  Serious Risks or Serious Adverse Events of the drug product

          -  The prohibition of the drug product

          -  Up to most current label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>HAN XU, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Medicine Invention Design, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HAN XU, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Medicine Invention Design, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HAN XU, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medicine Invention Design, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medicine Invention Design, Inc. (MIDI) - c/o - MIDINC Clinical Investigator Working Site</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MIDI Clinical Trial Sites -c/o- Dr. Han Xu - Physicians / Investigators / Laboratories assigned by CRO</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ohrp.cit.nih.gov/search/search.aspx?styp=bsc</url>
    <description>IORG0007849</description>
  </link>
  <link>
    <url>http://ohrp.cit.nih.gov/search/search.aspx?styp=bsc</url>
    <description>IRB00009424</description>
  </link>
  <link>
    <url>http://ohrp.cit.nih.gov/search/search.aspx?styp=bsc</url>
    <description>FWA00015357</description>
  </link>
  <link>
    <url>https://nppes.cms.hhs.gov/NPPESRegistry/NPIRegistrySearch.do?subAction=reset&amp;searchType=ind</url>
    <description>NPI: 1831468511 - INDIVIDUAL</description>
  </link>
  <link>
    <url>https://nppes.cms.hhs.gov/NPPESRegistry/NPIRegistrySearch.do?subAction=reset&amp;searchType=org</url>
    <description>NPI: 1023387701 - ORGANIZATION</description>
  </link>
  <results_reference>
    <citation>Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015 Aug;16(8):990-8. doi: 10.1016/S1470-2045(15)00121-7. Epub 2015 Jul 6.</citation>
    <PMID>26159065</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang JC, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R, Mok TS. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer. 2014 Feb;83(2):174-81. doi: 10.1016/j.lungcan.2013.11.021. Epub 2013 Dec 1.</citation>
    <PMID>24361280</PMID>
  </results_reference>
  <results_reference>
    <citation>Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24;352(8):786-92.</citation>
    <PMID>15728811</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medicine Invention Design, Inc</investigator_affiliation>
    <investigator_full_name>Han Xu, M.D., Ph.D., Sponsor-Investigator, IRB Chair</investigator_full_name>
    <investigator_title>M.D., Ph.D., Sponsor-Investigator, IORG Director, Monitor, IRB Chair</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>SNP</keyword>
  <keyword>Single Nucleotide Polymorphism</keyword>
  <keyword>Genetics</keyword>
  <keyword>Pharmacogenomic</keyword>
  <keyword>Pharmacogenetic</keyword>
  <keyword>gene</keyword>
  <keyword>genome</keyword>
  <keyword>genotype</keyword>
  <keyword>genotyping</keyword>
  <keyword>Oncology</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>Personalize</keyword>
  <keyword>Individualize</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Nilutamide</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

